Team KOODAC aims to develop oncoprotein degraders to target the drivers of solid tumours in children.
There is a major unmet clinical need for children with oncogene-driven cancers. To address this, KOODAC hopes to develop orally bioavailable drugs that can cross the blood-brain barrier that will dramatically improve cure rates for children with high-risk, oncogene-driven cancers.
The team hopes to focus on the development of Targeted Protein Degraders (TPDs) and Molecular Glue Degraders (MGDs) to target five key and previously undruggable oncoproteins (MYCN, EWSR1-FLI, DNAJB1-PRKACA, ALK, and PAX3/7-FOXO1), and conduct the preclinical studies needed for biomarker-driven clinical trials.
Bringing together experts in the fields of paediatric oncology, structural biology, medicinal chemistry and protein biochemistry, KOODAC's overarching goal is to directly impact oncogene-driven childhood cancers including neuroblastoma, medulloblastoma, Ewing sarcoma, fibrolamellar hepatocellular carcinoma, rhabdomyosarcoma and other cancers that deregulate these essential oncoproteins.
"I am humbled and incredibly energised to be one step closer to the opportunity to lead a team with outstanding and broad expertise in order to develop drugs that we intend to become the new standard of care for children with solid malignancies."